赛托生物(300583)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300583 赛托生物

已收盘 12-17 15:00:00

{"stockData":{"symbol":"300583","market":"SZ","secType":"STK","nameCN":"赛托生物","latestPrice":13.52,"timestamp":1765955025000,"preClose":13.84,"halted":0,"volume":3463000,"delay":0,"changeRate":-0.0231,"floatShares":186000000,"shares":190000000,"eps":-0.9105,"marketStatus":"已收盘","change":-0.32,"latestTime":"12-17 15:00:00","open":13.8,"high":13.8,"low":13.29,"amount":46750000,"amplitude":0.0368,"askPrice":13.53,"askSize":352,"bidPrice":13.52,"bidSize":26,"shortable":0,"etf":0,"ttmEps":-0.9105,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766021400000},"marketStatusCode":5,"adr":0,"adjPreClose":13.84,"symbolType":"stock","openAndCloseTimeList":[[1765935000000,1765942200000],[1765947600000,1765954800000]],"highLimit":15.22,"lowLimit":12.46,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":189702126,"isCdr":false,"pbRate":1.49,"roa":"--","roe":"--","epsLYR":-0.47,"committee":-0.081452,"marketValue":2565000000,"turnoverRate":0.0186,"status":1,"floatMarketCap":2517000000},"requestUrl":"/m/hq/s/300583/tweets","defaultTab":"tweets","newsList":[{"id":"2589850982","title":"赛托生物：截至2025年9月30日股东人数为13,737人","url":"https://stock-news.laohu8.com/highlight/detail?id=2589850982","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589850982?lang=zh_cn&edition=full","pubTime":"2025-12-05 11:36","pubTimestamp":1764905793,"startTime":"0","endTime":"0","summary":"证券之星消息，赛托生物(300583)12月04日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至11月30日公司的股东人数是多少？谢谢赛托生物回复：尊敬的投资者，您好！截至2025年9月30日，公司股东人数为13,737人。您可在定期报告中查询当期股东人数或者携带身份证及持股书面文件现场查阅。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500013435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2582355110","title":"赛托生物(300583.SZ)子公司收到糠酸莫米松化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582355110","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582355110?lang=zh_cn&edition=full","pubTime":"2025-11-11 15:55","pubTimestamp":1762847746,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛托生物(300583.SZ)发布公告，公司控股子公司山东斯瑞药业有限公司近日收到国家药品监督管理局签发的糠酸莫米松《化学原料药上市申请批准通知书》。糠酸莫米松具有强效抗炎作用，可用于吸入剂和局部皮肤外用药，用作吸入剂时，可与β2-肾上腺素能激动剂和/或长效乙酰胆碱受体拮抗剂组合，主要用于治疗哮喘;用作皮肤外用药时，可治疗湿疹、神经性皮炎、异位性皮炎及皮肤瘙痒症等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"赛托生物(300583.SZ)子公司收到糠酸莫米松化学原料药上市申请批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2580123267","title":"赛托生物(300583.SZ)：甲泼尼龙化学原料药上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2580123267","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580123267?lang=zh_cn&edition=full","pubTime":"2025-11-03 16:53","pubTimestamp":1762159996,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛托生物(300583.SZ)公告，公司控股子公司山东斯瑞药业有限公司近日收到国家药品监督管理局签发的甲泼尼龙《化学原料药上市申请批准通知书》。甲泼尼龙是中效、不含卤素皮质激素类药物，用于危重疾病的急救，还可用于内分泌失调、风湿性疾病、胶原性病、皮肤疾病、过敏反应、眼科疾病、胃肠道疾病、血液疾病、白血病、休克、脑水肿、多发性神经炎、脊髓炎及防止癌症化疗引起的呕吐等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"赛托生物(300583.SZ)：甲泼尼龙化学原料药上市申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2578938017","title":"赛托生物(300583.SZ)发布前三季度业绩，归母净亏损6923.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2578938017","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578938017?lang=zh_cn&edition=full","pubTime":"2025-10-28 16:41","pubTimestamp":1761640869,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛托生物(300583.SZ)发布2025年三季度报告，该公司前三季度营业收入为7.49亿元，同比减少2.07%。归属于上市公司股东的净亏损为6923.03万元。归属于上市公司股东的扣除非经常性损益的净亏损为7238.79万元。基本每股亏损为0.36元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2574510451","title":"赛托生物最新公告：子公司斯瑞药业收到地塞米松磷酸钠原料药CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2574510451","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574510451?lang=zh_cn&edition=full","pubTime":"2025-10-09 19:39","pubTimestamp":1760009979,"startTime":"0","endTime":"0","summary":"赛托生物(300583.SZ)公告称，公司控股子公司斯瑞药业近日收到欧洲药品质量管理局签发的地塞米松磷酸钠原料药欧洲药典适用性证书（CEP证书）。该证书有效期为自2025年10月1日起五年内有效。地塞米松磷酸钠是一种肾上腺皮质激素类药，主要用于过敏性与自身免疫性炎症性疾病。根据IQVIA数据统计，地塞米松磷酸钠原料药2024年全球需求量近10吨。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900029629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2569763353","title":"赛托生物：公司当前聚集于既定的产业升级战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2569763353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569763353?lang=zh_cn&edition=full","pubTime":"2025-09-23 11:33","pubTimestamp":1758598393,"startTime":"0","endTime":"0","summary":"证券之星消息，赛托生物(300583)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：能否介绍一下赛托生物在创新药领域的投资布局情况？赛托生物回复：尊敬的投资者，您好！公司积极关注行业中前景广阔的新兴领域，开展了一些探索性工作，短期内对公司的经营业绩不会造成重大影响。公司当前聚集于既定的产业升级战略，稳步推进原料药和制剂板块业务。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092300014482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2567489895","title":"赛托生物（300583）披露2025年半年度权益分派实施公告，9月16日股价上涨3.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567489895","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567489895?lang=zh_cn&edition=full","pubTime":"2025-09-16 22:48","pubTimestamp":1758034109,"startTime":"0","endTime":"0","summary":"截至2025年9月16日收盘，赛托生物报收于16.25元，较前一交易日上涨3.57%，最新总市值为30.83亿元。该股当日开盘15.69元，最高16.6元，最低15.59元，成交额达1.23亿元，换手率为4.09%。公司近日发布公告称，2025年半年度权益分派方案已获股东大会审议通过。本次权益分派股权登记日为2025年9月23日，除权除息日为2025年9月24日。分红对象为截至股权登记日在中国结算深圳分公司登记在册的全体股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091600038494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2567515727","title":"股市必读：赛托生物（300583）9月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2567515727","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567515727?lang=zh_cn&edition=full","pubTime":"2025-09-15 04:08","pubTimestamp":1757880497,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，赛托生物报收于15.81元，下跌0.63%，换手率1.4%，成交量2.6万手，成交额4121.65万元。董秘最新回复投资者： 据媒体报道，赛托生物与由生成式人工智能 驱动的临床阶段生物科技公司英硅智能达成战略合作，旨在运用前沿AI技术和优化生物系统工程化改造过程中的关键步骤，用于合成生物学研究及创新药物的研发。交易信息汇总资金流向9月12日主力资金净流出412.3万元；游资资金净流入114.59万元；散户资金净流入297.72万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500001269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2566915564","title":"股市必读：赛托生物（300583）9月11日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2566915564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566915564?lang=zh_cn&edition=full","pubTime":"2025-09-12 02:29","pubTimestamp":1757615352,"startTime":"0","endTime":"0","summary":"截至2025年9月11日收盘，赛托生物报收于15.91元，上涨0.06%，换手率2.0%，成交量3.73万手，成交额5878.71万元。董秘最新回复投资者： 请问，公司哪些产品属于化学制药？公司本次投资金额及持有爱萨尔生物股份占比很少，短期内对公司的经营业绩不会造成重大影响。当日关注点来自交易信息汇总：9月11日主力资金净流出886.14万元，散户资金净流入826.05万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091200001376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2566575179","title":"赛托生物：参股爱萨尔生物探索细胞治疗领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2566575179","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566575179?lang=zh_cn&edition=full","pubTime":"2025-09-11 15:57","pubTimestamp":1757577431,"startTime":"0","endTime":"0","summary":"爱萨尔生物官网显示其核心产品管线覆盖间充质干细胞药品、诱导多能干细胞药品和免疫细胞药品三大领域。公司参股公司爱萨尔生物的主要产品是创新型生物制品，属于I类新药，公司参股爱萨尔生物是为了以少量资金探索、布局细胞治疗这一医疗行业中前景广阔的新兴领域，主要着眼于医药领域的未来发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091100023262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2564311722","title":"股市必读：赛托生物（300583）9月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2564311722","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564311722?lang=zh_cn&edition=full","pubTime":"2025-09-04 04:39","pubTimestamp":1756931950,"startTime":"0","endTime":"0","summary":"截至2025年9月3日收盘，赛托生物报收于15.85元，下跌2.16%，换手率1.76%，成交量3.27万手，成交额5245.27万元。董秘最新回复投资者： 请问董秘：公司自投资金建设了专门生产鼻喷雾剂的工厂，并已进入设备安装调试阶段，产品是自己拿到批文生产，还是代工生产别人公司产品？当日关注点来自交易信息汇总：9月3日主力资金净流出311.93万元，散户资金净流入380.27万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090400003179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2564809350","title":"赛托生物：公司产品品种较多生产周期较长需备货","url":"https://stock-news.laohu8.com/highlight/detail?id=2564809350","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564809350?lang=zh_cn&edition=full","pubTime":"2025-09-03 15:04","pubTimestamp":1756883084,"startTime":"0","endTime":"0","summary":"证券之星消息，赛托生物09月03日在投资者关系平台上答复投资者关心的问题。公司产品品种较多，生产过程中的微生物转化需要多批次同步运行，且产品生产环节较多决定了生产周期较长，同时下游客户需求多样，每种产品均需有一定的备货量。公司遵循《企业会计准则》的相关规定计提存货减值，存货减值的金额为单一存货账面价值与可变现净值之间的差额。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090300019290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2562631797","title":"赛托生物（300583）2025年中报简析：净利润同比下降498.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562631797","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562631797?lang=zh_cn&edition=full","pubTime":"2025-08-27 06:28","pubTimestamp":1756247320,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期赛托生物发布2025年中报。根据财报显示，赛托生物净利润同比下降498.8%。截至本报告期末，公司营业总收入5.08亿元，同比下降10.39%，归母净利润-5268.71万元，同比下降498.8%。按单季度数据看，第二季度营业总收入2.48亿元，同比下降23.07%，第二季度归母净利润-2517.86万元，同比下降348.29%。租赁负债变动幅度为-93.32%,原因:报告期内经营租赁房产减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700008887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583"],"gpt_icon":0},{"id":"2562834227","title":"化学制药行业26日主力净流出28.8亿元，赛托生物、汉商集团居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2562834227","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562834227?lang=zh_cn&edition=full","pubTime":"2025-08-26 15:54","pubTimestamp":1756194885,"startTime":"0","endTime":"0","summary":"8月26日，化学制药行业下跌0.96%，今日主力资金流出28.8亿元，成分股42只上涨，54只下跌。主力资金净流出居前的分别为赛托生物、汉商集团、山河药辅、新华制药、森萱医药。序号代码名称最新价涨跌幅主力净流入主力净占比1002001新 和 成25.02.251.30亿元11.43%2002082万邦德8.719.971.15亿元28.85%3002099海翔药业6.416.137877.23万元17.83%4688166博瑞医药109.50.07835.66万元8.0%5002370亚太药业6.851.185457.65万元8.82%6002102能特科技4.19-0.714635.56万元11.73%7600267海正药业11.490.354624.14万元7.24%8002332仙琚制药11.50.74516.04万元11.92%9000513丽珠集团41.770.413242.33万元6.5%10603538美诺华27.380.333006.87万元4.66%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26155452697308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","BK0239","600774","300583","BK1574","01477","BK0209"],"gpt_icon":0},{"id":"2562213252","title":"图解赛托生物中报：第二季度单季净利润同比下降348.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562213252","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562213252?lang=zh_cn&edition=full","pubTime":"2025-08-26 01:41","pubTimestamp":1756143699,"startTime":"0","endTime":"0","summary":"证券之星消息，赛托生物2025年中报显示，公司主营收入5.08亿元，同比下降10.39%；归母净利润-5268.71万元，同比下降498.8%；扣非净利润-5348.16万元，同比下降1159.04%；其中2025年第二季度，公司单季度主营收入2.48亿元，同比下降23.07%；单季度归母净利润-2517.86万元，同比下降348.29%；单季度扣非净利润-2566.85万元，同比下降823.33%；负债率37.66%，投资收益409.14万元，财务费用1703.66万元，毛利率12.01%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082600003376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583"],"gpt_icon":0},{"id":"2562246788","title":"赛托生物(300583.SZ)发布上半年业绩，由盈转亏5268.71万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562246788","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562246788?lang=zh_cn&edition=full","pubTime":"2025-08-25 19:44","pubTimestamp":1756122242,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛托生物(300583.SZ)发布2025年半年度报告，报告期内，公司实现营业收入5.08亿元，同比下降10.39%。归属于上市公司股东净亏损5268.71万元。归属于上市公司股东的扣除非经常性损益净亏损5348.16万元。基本每股亏损0.28元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"赛托生物(300583.SZ)发布上半年业绩，由盈转亏5268.71万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2560416201","title":"赛托生物：动保板块布局多款兽药原料药项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2560416201","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560416201?lang=zh_cn&edition=full","pubTime":"2025-08-20 08:58","pubTimestamp":1755651492,"startTime":"0","endTime":"0","summary":"证券之星消息，赛托生物(300583)08月19日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在兽药领域有什么项目或产品？竞争力如何？赛托生物回复：尊敬的投资者，您好！公司动保板块布局有硫酸新霉素、酒石酸泰万菌素等多款兽药原料药项目，动保原料药市场价格受经济周期影响波动较大，当前公司正在积极的开拓市场，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082000009319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2555590070","title":"赛托生物：公司将把握政策机遇做优做强主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2555590070","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555590070?lang=zh_cn&edition=full","pubTime":"2025-07-29 20:51","pubTimestamp":1753793507,"startTime":"0","endTime":"0","summary":"证券之星消息，赛托生物(300583)07月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘：随着集采政策的改变，原料药竞争环境是否开始改善，最近国家反卷，是否原料药也有这方面涉及，对公司是不利好？赛托生物回复：尊敬的投资者，您好！随着集采政策的调整，医药产业链的竞争环境将会有所变化。公司将把握政策机遇，聚焦于将赛托生物打造成集“医药中间体、原料药和成品制剂为一体”的生物技术企业的中长期发展战略，做优做强主业。 感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900037436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2548584538","title":"熊去氧胆酸概念盘中跳水，赛托生物跌1.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548584538","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548584538?lang=zh_cn&edition=full","pubTime":"2025-07-02 10:43","pubTimestamp":1751424200,"startTime":"0","endTime":"0","summary":"07月02日，熊去氧胆酸概念盘中跳水，截至10点43分，熊去氧胆酸概念整体指数下跌2.03%，报1196.650点。从个股上来看，该概念的成分股中，赛托生物跌1.67%，川宁生物、人福医药、共同药业跌幅居前。从资金上来看，截止发稿，熊去氧胆酸概念主力净流入为-3.42亿，其中白云山受到资金热捧，主力净流入441.54万；拉长时间线来看，该板块近20日主力资金净流入-31.51亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702104320a7298bfa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702104320a7298bfa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0185","300583","BK0096","600079","BK0070","BK0188","BK0012","600332","BK0028"],"gpt_icon":0},{"id":"2547091738","title":"赛托生物最新公告：子公司收到化学原料药欧洲CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2547091738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547091738?lang=zh_cn&edition=full","pubTime":"2025-06-30 20:40","pubTimestamp":1751287225,"startTime":"0","endTime":"0","summary":"赛托生物(300583.SZ)公告称，公司控股子公司斯瑞药业近日收到欧洲药品质量管理局签发的原料药欧洲药典适用性证书（CEP证书）。该证书涉及的原料药名称为糠酸莫米松。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025063000031274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766013167445,"stockEarnings":[{"period":"1week","weight":-0.065},{"period":"1month","weight":-0.1587},{"period":"3month","weight":-0.1382},{"period":"6month","weight":-0.1825},{"period":"1year","weight":-0.421},{"period":"ytd","weight":-0.3076}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0256},{"period":"3month","weight":0.0101},{"period":"6month","weight":0.1519},{"period":"1year","weight":0.1514},{"period":"ytd","weight":0.1547}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东赛托生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13737人(较上一季度增加7.91%)","perCapita":"13550股","listingDate":"2017-01-06","address":"山东省菏泽市定陶区东外环路南段","registeredCapital":"18970万元","survey":"　　山东赛托生物科技股份有限公司的主营业务是应用基因工程技术和微生物转化技术制造并销售甾体药物原料和中间体。公司的主要产品是雄烯二酮（4-AD）、雄二烯二酮（ADD）、9-羟基雄烯二酮（9OH-AD）、四烯物（3TR）、甲羟环氧孕酮（8DM）等甾体药物原料及中间体。公司入围国家工业和信息化部第五批国家级绿色工厂，获评山东省十强产业集群领军企业，子公司斯瑞药业获得山东省专精特新中小企业荣誉称号。","listedPrice":40.29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛托生物(300583)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛托生物(300583)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛托生物,300583,赛托生物股票,赛托生物股票老虎,赛托生物股票老虎国际,赛托生物行情,赛托生物股票行情,赛托生物股价,赛托生物股市,赛托生物股票价格,赛托生物股票交易,赛托生物股票购买,赛托生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛托生物(300583)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛托生物(300583)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}